The peptide that cuts the blood supply to white fat tissue — dramatic preclinical weight loss but kidney toxicity signals that stalled its clinical development.
Adipotide (FTPP — Fat-Targeted ProApoptotic Peptide) is an experimental peptide designed by Kolonin and Arap at MD Anderson. It combines two domains: a homing sequence that binds prohibitin on the vasculature of white adipose tissue, and a proapoptotic sequence that triggers cell death once bound. Net effect: selectively destroys the blood supply to white fat, which kills the fat cells behind it.
Preclinical data in obese primates was striking — 7–10% body weight loss with 27% fat mass reduction over 4 weeks. But early Phase 1 human trials raised dose-dependent kidney toxicity concerns that have effectively stalled clinical development.
Not FDA approved. Phase 1 trials on pause due to nephrotoxicity signal. Research chemical only; strongly not recommended outside of supervised research settings.
The homing domain binds prohibitin, a receptor selectively expressed on the endothelial cells of white adipose tissue vasculature. This is the molecular basis for tissue selectivity.
The proapoptotic domain triggers cell death in the bound endothelium. Fat tissue loses its blood supply, adipocytes starve and die, adipose tissue is reabsorbed.
Kidneys filter large quantities of blood and have a vascular bed that unfortunately expresses enough prohibitin-like targets for Adipotide to accumulate. Phase 1 trials saw dose-dependent acute kidney injury, which is the major barrier to clinical development.
| Benefit | Evidence |
|---|---|
| Weight loss (primate) | Barnhart 2011 Sci Transl Med: 11% weight loss in obese rhesus macaques over 28 days |
| Fat-mass specific loss | Preserved lean mass in primate studies — drop was specifically from white fat |
| Metabolic improvements | Improved insulin sensitivity in animal models |
| Phase 1 human | Limited trials; weight loss signal confirmed but nephrotoxicity caused development delays |
GLP-1 agonists (semaglutide, tirzepatide, retatrutide) have largely replaced the clinical interest in Adipotide. The safety margin is just much better.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeGiven the kidney toxicity signal in Phase 1 human trials, we don’t publish a recommended dosing protocol for Adipotide. Users who still choose to experiment typically base doses on the primate-study range (10 mg/kg/day × 28 days), but this is the same dose range that raised the kidney concern. Modern GLP-1 agonists produce comparable weight loss with a radically better safety margin.
Standard lyophilized-powder reconstitution (2 mL BAC water per 10 mg vial) applies. See the general reconstitution pattern elsewhere in the library. Given the safety caveats above, we don’t provide a dose-volume table for Adipotide.
Use our free peptide calculator to figure out your reconstitution volume, draw amount, and syringe units.
Open Peptide CalculatorDosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
If you’re considering Adipotide for personal use, talk to a nephrologist first. Bloodwork before, mid-cycle, and after is non-negotiable. Semaglutide or tirzepatide give you equivalent fat loss without this concern — strongly consider those first.
Adipotide (FTPP) is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
StackTrax’s preferred partner NextGen Peptides does not currently carry Adipotide (FTPP)in their catalog, which is why you don’t see a direct purchase link here. Other major research-chemical suppliers carry it; we don’t specifically recommend one for this compound.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeDisclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.